Published in J Virol on March 01, 2001
Flexibility of the adenovirus fiber is required for efficient receptor interaction. J Virol (2003) 1.49
Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog (2007) 1.28
Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng (2008) 1.28
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol (2002) 0.96
A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One (2009) 0.94
Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol (2007) 0.94
Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J Virol (2002) 0.92
Gene Therapy Applications to Cancer Treatment. J Biomed Biotechnol (2003) 0.90
Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J Virol (2006) 0.89
Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol (2010) 0.88
Development of viral vectors for use in cardiovascular gene therapy. Viruses (2010) 0.81
Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody. J Mol Biol (2009) 0.80
Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses. J Virol (2005) 0.79
Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One (2014) 0.77
Adenoviral gene therapy, radiation, and prostate cancer. Rev Urol (2005) 0.77
Reduced infectivity of adenovirus type 5 particles and degradation of entering viral genomes associated with incomplete processing of the preterminal protein. J Virol (2012) 0.77
Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques (1990) 13.62
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science (1993) 10.16
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol (1996) 4.97
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol (1998) 3.32
Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J (1993) 3.27
Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science (1999) 3.24
Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure (1994) 2.80
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 2.64
Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol (1994) 2.56
Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science (1999) 2.56
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol (1996) 2.52
Image reconstruction reveals the complex molecular organization of adenovirus. Cell (1991) 2.42
A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein. Nature (1999) 2.35
Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol (1996) 2.14
Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol (1995) 1.88
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol (1998) 1.88
Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol (1996) 1.85
Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol (1997) 1.79
Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol (2000) 1.65
Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol (1996) 1.61
General analysis of receptor-mediated viral attachment to cell surfaces. Biophys J (1990) 1.58
Structure of adenovirus complexed with its internalization receptor, alphavbeta5 integrin. J Virol (1999) 1.57
Deletion analysis of functional domains in baculovirus-expressed adenovirus type 2 fiber. Virology (1991) 1.52
A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol (1995) 1.42
Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther (1995) 1.42
New triple-helical model for the shaft of the adenovirus fibre. J Mol Biol (1992) 1.42
A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol (1999) 1.39
A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J Virol (1999) 1.39
Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol (1999) 1.37
Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol (2000) 1.37
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol (2000) 1.33
Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. J Virol (1999) 1.28
Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther (1999) 1.22
Genetic targeting of adenoviral vectors. Mol Ther (2000) 1.18
Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J Gen Virol (1999) 1.16
Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol (1999) 1.08
Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res (1997) 1.08
Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density. J Virol (1999) 1.02
Structure of adenovirus fibre. I. Analysis of crystals of fibre from adenovirus serotypes 2 and 5 by electron microscopy and X-ray crystallography. J Mol Biol (1990) 1.02
Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther (2000) 0.90
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol (1994) 3.42
H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. EMBO J (1992) 3.21
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol (1995) 2.41
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 2.38
An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng (1993) 2.31
Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J Virol (1998) 2.20
MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A (2000) 2.12
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J Biol Chem (1999) 2.04
Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity (1997) 2.04
Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol (1991) 2.04
Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol (1998) 1.99
Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? Br Med J (1972) 1.95
Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J (1997) 1.82
Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding. Biochemistry (1989) 1.77
Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol (2001) 1.72
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Eating disorder examination questionnaire: norms for young adolescent girls. Behav Res Ther (2001) 1.59
Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol (1985) 1.58
Structure of adenovirus complexed with its internalization receptor, alphavbeta5 integrin. J Virol (1999) 1.57
Protein engineering of subtilisin BPN': enhanced stabilization through the introduction of two cysteines to form a disulfide bond. Biochemistry (1987) 1.56
Isolation of a cDNA that hybrid selects antiproliferative mRNA from rat liver. Biochem Biophys Res Commun (1989) 1.54
Complications of 278 consecutive abdominoplasties. J Plast Reconstr Aesthet Surg (2006) 1.52
Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol (1981) 1.50
DNA binding and heteromerization of the Drosophila transcription factor chorion factor 1/ultraspiracle. Proc Natl Acad Sci U S A (1992) 1.49
Urinary D-glucaric acid excretion and total liver content of cytochrome P-450 in guinea-pigs: relationship during enzyme induction and following inhibition of protein synthesis. Biochem Pharmacol (1973) 1.45
Association of p130CAS with phosphatidylinositol-3-OH kinase mediates adenovirus cell entry. J Biol Chem (2000) 1.43
Primary prevention of eating disorders: might it do more harm than good? Int J Eat Disord (1997) 1.42
A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J Virol (1999) 1.39
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem (2000) 1.38
The engineering of binding affinity at metal ion binding sites for the stabilization of proteins: subtilisin as a test case. Biochemistry (1988) 1.37
Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol (2000) 1.37
Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70. J Biol Chem (2000) 1.36
Interactions of soluble recombinant integrin alphav beta5 with human adenoviruses. J Virol (1998) 1.36
Optimization of growth methods and recombinant protein production in BTI-Tn-5B1-4 insect cells using the baculovirus expression system. Biotechnol Prog (1993) 1.34
Enuresis. Pediatr Clin North Am (1974) 1.32
Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci U S A (1984) 1.31
Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Annu Rev Immunol (1988) 1.31
Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol (1986) 1.29
Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J Biol Chem (1989) 1.26
Cell cycle activity and expression of prohibitin mRNA. J Cell Physiol (1993) 1.26
Hypothermic arrest and potassium arrest: metabolic and myocardial protection during elective cardiac arrest. Circ Res (1975) 1.25
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest (1982) 1.20
A single amino acid in the adenovirus type 37 fiber confers binding to human conjunctival cells. J Virol (1999) 1.18
A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37. Virology (2001) 1.15
Proteases of enhanced stability: characterization of a thermostable variant of subtilisin. Proteins (1986) 1.14
Cloning of the gene for phosphoribulokinase activity from Rhodobacter sphaeroides and its expression in Escherichia coli. J Bacteriol (1987) 1.10
Acute withdrawal of nasal CPAP in obstructive sleep apnea does not cause a rise in stress hormones. Sleep (1996) 1.09
Matrix valency regulates integrin-mediated lymphoid adhesion via Syk kinase. J Cell Biol (1999) 1.08
Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther (2001) 1.08
Are antibiotic drugs needed for the treatment of upper respiratory tract infections in infants? Can Med Assoc J (1972) 1.07
Restriction of complement-mediated membrane damage by the eighth component of complement: a dual role for C8 in the complement attack sequence. J Immunol (1979) 1.06
Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin beta5. J Virol (2000) 1.05
Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein. J Gen Virol (1998) 1.04
Structural analysis of a fiber-pseudotyped adenovirus with ocular tropism suggests differential modes of cell receptor interactions. J Virol (2001) 1.04
Cellular protection during myocardial ischemia: the development and characterization of a procedure for the induction of reversible ischemic arrest. Circulation (1976) 1.03
Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats. J Virol (1991) 1.01
Increased hepatic microsomal enzyme activity from occupational exposure to certain organochlorine pesticides. Nature (1972) 1.01
Complement, viruses, and virus-infected cells. Springer Semin Immunopathol (1983) 1.00
Recovery from cardiac bypass and elective cardiac arrest. The metabolic consequences of various cardioplegic procedures in the isolated rat heart. Circ Res (1974) 0.99
Doppler echocardiography in elderly patients with ejection systolic murmurs. Postgrad Med J (1991) 0.99
Enuresis treated by an improved waking apparatus. Can Med Assoc J (1972) 0.99
CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol (1988) 0.99
Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions. J Immunol (1986) 0.98
Myocardial protection during ischemic cardiac arrest. The importance of magnesium in cardioplegic infusates. J Thorac Cardiovasc Surg (1978) 0.97
Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2). J Immunol (1986) 0.96
Diagnosis and treatment of throat infections in children. Can Med Assoc J (1971) 0.96
Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng (1994) 0.95
Crystallization and preliminary X-ray diffraction analysis of human adenovirus. Virology (2010) 0.94
Diabetes and the survival and recovery of the anoxic myocardium. J Mol Cell Cardiol (1975) 0.94
Studies into the transplantation biology of ultraviolet light-induced tumors. Transplantation (1977) 0.94
Cochlear implants for younger children: a preliminary description of the parental decision process and outcomes. Am Ann Deaf (2000) 0.93
CR2 complement receptor. J Invest Dermatol (1990) 0.93
Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350. J Immunol (1988) 0.93
Methods to detect and quantitate complement activation. Springer Semin Immunopathol (1983) 0.93
Fibrinogen and glycoprotein IIb/IIIa localization during platelet adhesion. Localization to the granulomere and at sites of platelet interaction. Am J Pathol (1990) 0.93
Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins. Oncogene (2000) 0.92
Recent structural solutions for antibody neutralization of viruses. Trends Microbiol (1997) 0.90
Regions of evolutionary conservation between the rat and human prohibitin-encoding genes. Gene (1995) 0.89
Role of toxic ingredients in silicone oils in the induction of increased corneal endothelial permeability. Lens Eye Toxic Res (1992) 0.89
Production of functional antibodies generated in a nonlytic insect cell expression system. Protein Expr Purif (2001) 0.88
Skin wound-enhanced survival and myelocytopoiesis in mice after whole-body irradiation. Acta Radiol Oncol (1981) 0.88
Growth and development from early to midadolescence of children with X and Y chromosome aneuploidy: the Toronto Study. Birth Defects Orig Artic Ser (1986) 0.87
Benefit of aggressive multimodality therapy with autologous stem cell support for intra-abdominal desmoplastic small round cell tumor. Bone Marrow Transplant (1998) 0.87
Assignment of the human prohibitin gene (PHB) to chromosome 17 and identification of a DNA polymorphism. Genomics (1991) 0.87
Viral purging of haematological autografts: should we sneeze on the graft? Bone Marrow Transplant (2007) 0.87
Synthesis of adenoviral targeting molecules by intein-mediated protein ligation. Gene Ther (2003) 0.86
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant (2003) 0.86
Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther (2000) 0.86
Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol (1998) 0.85